• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

    2/3/22 4:41:28 PM ET
    $SPNE
    Medical Specialities
    Health Care
    Get the next $SPNE alert in real time by email
    SC 13G/A 1 us81255t1088_020322.txt us81255t1088_020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SeaSpine Holdings Corp -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 81255T108 -------------------------------------------------------- (CUSIP Number) December 31, 2021 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 81255T108 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 2446101 (6) Shared voting power 0 (7) Sole dispositive power 2491536 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 2491536 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 6.8% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- SeaSpine Holdings Corp Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 5770 ARMADA DRIVE CARLSBAD CA 92008 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 55 East 52nd Street New York, NY 10055 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 2491536 Percent of class 6.8% Number of shares as to which such person has: Sole power to vote or to direct the vote 2446101 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 2491536 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of SeaSpine Holdings Corp. No one person's interest in the common stock of SeaSpine Holdings Corp is more than five percent of the total outstanding common shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 3, 2022 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary Aperio Group, LLC BlackRock Advisors, LLC BlackRock Investment Management (UK) Limited BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BLACKROCK, INC., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Christopher Meade, Daniel Waltcher, Una Neary, Richard Cundiff, Charles Park, Enda McMahon, Arlene Klein, Con Tzatzakis, Karen Clark, David Maryles, Daniel Ronnen, John Stelley, Daniel Riemer, Elizabeth Kogut, Maureen Gleeson, Daniel Kalish and Spencer Fleming acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, is acting certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, Including without limitation Forms 3, 4, 5, 13D, 13F, 13G and 13H and any amendments to any of the Foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 8th day of December, 2015 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 2nd day of January, 2019. BLACKROCK, INC. By:_ /s/ Daniel Waltcher Name: Daniel Waltcher Title: Deputy General Counsel
    Get the next $SPNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPNE

    DatePrice TargetRatingAnalyst
    11/2/2022$12.00 → $6.75Buy → Hold
    Truist
    4/22/2022$27.00 → $21.00Overweight
    Cantor Fitzgerald
    4/13/2022$20.00Buy
    Truist
    12/21/2021$25.00 → $20.00Buy
    Truist Securities
    10/28/2021$100.00Buy
    Loop Capital
    More analyst ratings

    $SPNE
    SEC Filings

    See more
    • SEC Form CT ORDER filed by SeaSpine Holdings Corporation

      CT ORDER - SeaSpine Holdings Corp (0001637761) (Filer)

      4/3/23 8:19:25 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by SeaSpine Holdings Corporation

      15-12G - SeaSpine Holdings Corp (0001637761) (Filer)

      1/17/23 4:31:53 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by SeaSpine Holdings Corporation

      EFFECT - SeaSpine Holdings Corp (0001637761) (Filer)

      1/12/23 12:15:22 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Leadership Updates

    Live Leadership Updates

    See more
    • SeaSpine® Announces New Senior Leadership Team Appointments

      CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic, previously the Company's Senior Vice President, Chief Financial Officer, has assumed expanded responsibilities and the title of Chief Operating and Financial Officer. In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources. With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team. Mr. Bostjancic has served as SeaSpine's Chief Financial Officer since 2015. He has been an influentia

      5/3/22 4:04:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SeaSpine® Announces New Senior Leadership Team Appointments

      CARLSBAD, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the elevation of Dr. Frank Vizesi to Chief Scientific Officer and Shaeffer Bannigan to Vice President, Product Development, Spinal Implants. With his promotion, Mr. Bannigan joins the SeaSpine Senior Leadership Team. Dr. Vizesi joined SeaSpine in 2015 as Director, Research and Development, Orthobiologics. He quickly elevated the approach and defined the vision for delivering best-in-class orthobiologics procedural solutions. Under Dr. Vizesi's leadership, the team deepened

      3/7/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SeaSpine Appoints Seasoned Healthcare Executive to its Board of Directors

      CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company's Audit Committee. With the appointment of Ms. Steinway, the SeaSpine Board of Directors now consists of nine directors, eight of whom are independent. Ms. Steinway brings over 15 years of experience in the medical device industry, having worked in various strategy, sales and finance functions throughout her career. Currently, she i

      12/14/21 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SeaSpine downgraded by Truist with a new price target

      Truist downgraded SeaSpine from Buy to Hold and set a new price target of $6.75 from $12.00 previously

      11/2/22 6:34:40 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Cantor Fitzgerald resumed coverage on SeaSpine with a new price target

      Cantor Fitzgerald resumed coverage of SeaSpine with a rating of Overweight and set a new price target of $21.00 from $27.00 previously

      4/22/22 9:10:58 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Truist resumed coverage on SeaSpine with a new price target

      Truist resumed coverage of SeaSpine with a rating of Buy and set a new price target of $20.00

      4/13/22 7:17:39 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:21:07 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:51 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:35 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      1/31/23 1:58:01 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      2/14/22 11:45:59 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      2/3/22 4:41:28 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaSpine Announces 100th Placement of 7D FLASH™ Navigation System

      CARLSBAD, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the placement of its 100th 7D FLASH™ Navigation System globally. The 7D FLASH™ Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures with less radiation exposure. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing fru

      12/27/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221118005106/en/ Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Sen

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      LEWISVILLE, Texas and CARLSBAD, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Senior Vice President from 2015 through 2022, and as

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities

    $SPNE
    Financials

    Live finance-specific insights

    See more
    • SeaSpine to Report Third Quarter 2022 Financial Results on November 1, 2022

      CARLSBAD, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Tuesday, November 1, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. To listen to the live webcast and a replay, please visit the Investors section of the SeaSpine website at: https://www.seaspine.com/. About SeaSpine SeaSpine (www.seaspine.com) is a global medical technology company focused on the des

      10/24/22 7:00:00 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company

      Highly complementary spine and orthopedics portfoliosOne of the industry's broadest biologics and regenerative technology offeringsDifferentiated and synergistic enabling technologiesMeaningful cross-selling revenue synergies and cost savingsFinancial strength to pursue growth investments without need for immediate equity financing Expected to be adjusted EBITDA accretive to Orthofix by the second year following close including cost savings Companies to host joint conference call and webcast today at 8:00 a.m. ET LEWISVILLE, Texas and CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) --  Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpin

      10/11/22 6:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • SeaSpine Reports 19% Revenue Growth and Record Quarterly Revenue for Second Quarter 2022 and Raises Full Year 2022 Revenue Guidance

      CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today second quarter financial results for the three-months ended June 30, 2022. Summary Second Quarter 2022 Financial Results and Recent Highlights Total revenue of $56.3 million, an increase of 19% year-over-yearU.S. revenue of $49.5 million, an increase of 16% year-over-year U.S. spinal implants and enabling technologies revenue of $25.0 million, an increase of 17% year-over-yearU.S. orthobiologics revenue of $24.5 million, an increase of 16% year-over-year International reve

      8/2/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care